JP7759693B2 - モンテルカストおよびペプチドの新規接合体 - Google Patents
モンテルカストおよびペプチドの新規接合体Info
- Publication number
- JP7759693B2 JP7759693B2 JP2021514112A JP2021514112A JP7759693B2 JP 7759693 B2 JP7759693 B2 JP 7759693B2 JP 2021514112 A JP2021514112 A JP 2021514112A JP 2021514112 A JP2021514112 A JP 2021514112A JP 7759693 B2 JP7759693 B2 JP 7759693B2
- Authority
- JP
- Japan
- Prior art keywords
- hyp
- lys
- peptide
- tyr
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/105703 | 2018-09-14 | ||
| CN2018105703 | 2018-09-14 | ||
| CNPCT/CN2018/119072 | 2018-12-04 | ||
| CN2018119072 | 2018-12-04 | ||
| PCT/CN2019/105832 WO2020052677A1 (en) | 2018-09-14 | 2019-09-14 | New conjugates of montelukast and peptides |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500437A JP2022500437A (ja) | 2022-01-04 |
| JPWO2020052677A5 JPWO2020052677A5 (https=) | 2022-09-21 |
| JP2022500437A5 JP2022500437A5 (https=) | 2022-09-21 |
| JP7759693B2 true JP7759693B2 (ja) | 2025-10-24 |
Family
ID=69777394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514112A Active JP7759693B2 (ja) | 2018-09-14 | 2019-09-14 | モンテルカストおよびペプチドの新規接合体 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11680082B2 (https=) |
| EP (2) | EP4253404A3 (https=) |
| JP (1) | JP7759693B2 (https=) |
| KR (1) | KR102946621B1 (https=) |
| CN (2) | CN111601618A (https=) |
| AU (1) | AU2019338582B2 (https=) |
| BR (1) | BR112021004823A2 (https=) |
| CA (1) | CA3112420A1 (https=) |
| DK (1) | DK3678705T5 (https=) |
| ES (1) | ES2956509T3 (https=) |
| FI (1) | FI3678705T3 (https=) |
| HR (1) | HRP20230946T1 (https=) |
| HU (1) | HUE062848T2 (https=) |
| IL (1) | IL281426A (https=) |
| LT (1) | LT3678705T (https=) |
| MX (1) | MX2021002657A (https=) |
| MY (1) | MY205435A (https=) |
| PL (1) | PL3678705T3 (https=) |
| PT (1) | PT3678705T (https=) |
| RS (1) | RS64436B1 (https=) |
| SA (1) | SA521421448B1 (https=) |
| SG (1) | SG11202102119RA (https=) |
| SI (1) | SI3678705T1 (https=) |
| SM (1) | SMT202300210T1 (https=) |
| TW (1) | TWI875712B (https=) |
| WO (1) | WO2020052677A1 (https=) |
| ZA (1) | ZA202101398B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020000029A (es) * | 2017-07-05 | 2020-08-06 | Jiangyin Mucocare Pharmaceutical Co Ltd | Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. |
| MX2022003057A (es) * | 2019-09-14 | 2022-06-16 | Jiangyin Usun Pharmaceutical Co Ltd | Nuevos peptidos. |
| CA3160167A1 (en) * | 2019-12-02 | 2021-06-10 | Ming Gu | Peptides and their use in the treatment of inflammation |
| WO2021207606A1 (en) * | 2020-04-10 | 2021-10-14 | University Of Georgia Research Foundation, Inc. | Methods for treatment of coronavirus infections |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102596264B1 (ko) * | 2020-11-30 | 2023-11-01 | 주식회사 바이오빛 | 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물 |
| US20240165247A1 (en) * | 2021-03-17 | 2024-05-23 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptide conjugates |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| WO2023225107A1 (en) * | 2022-05-17 | 2023-11-23 | Emory University | Diroximel fumarate, inhalation administration methods, pharmaceutical uses and compositions |
| EP4665372A1 (en) * | 2023-02-13 | 2025-12-24 | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | New multi-functional oligopeptides |
| WO2024260465A1 (en) * | 2023-06-22 | 2024-12-26 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New multi-functional oligopeptides |
| TW202535906A (zh) * | 2023-10-23 | 2025-09-16 | 大陸商安利提沙(上海)製藥有限公司 | 新型短鏈肽及其衍生物 |
| KR20250075990A (ko) * | 2023-11-22 | 2025-05-29 | 한도숙 | 상처 치료 또는 피부 주름형성 억제용 조성물 |
| WO2025195444A1 (en) | 2024-03-20 | 2025-09-25 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New use of peptides derived from vasoactive intestinal peptide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005524677A (ja) | 2002-02-22 | 2005-08-18 | ニュー リバー ファーマシューティカルズ インコーポレイテッド | 活性物質送達系及び活性物質を保護し投与する方法 |
| JP2013504579A (ja) | 2009-09-09 | 2013-02-07 | ファーマイン コーポレーション | 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法 |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| WO2003020200A2 (en) * | 2000-11-16 | 2003-03-13 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
| PL374646A1 (en) | 2002-07-08 | 2005-10-31 | Pliva-Istrazivacki Institutt D.O.O. | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| US20050107612A1 (en) | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
| CA2522007A1 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Methods of preventing or treating respiratory conditions |
| JP4764818B2 (ja) * | 2003-04-11 | 2011-09-07 | メディミューン,エルエルシー | 組換えil−9抗体およびその使用 |
| CN101123878A (zh) | 2003-07-29 | 2008-02-13 | 信号研发控股有限责任公司 | 氨基酸前药 |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| ES2337915T3 (es) | 2004-10-27 | 2010-04-30 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Conjugados con adtividad antiinflamatoria. |
| TW200740441A (en) * | 2005-06-17 | 2007-11-01 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
| CN102068432A (zh) | 2011-01-11 | 2011-05-25 | 李仲昆 | 一种由他定类和白三烯拮抗剂组成的外用复方组合物 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| CN116898848A (zh) | 2012-01-18 | 2023-10-20 | 苏州泰飞尔医药有限公司 | 治疗肺部疾病的高穿透力前药组合物和医药组合物 |
| WO2014164285A2 (en) * | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| US20160060328A1 (en) * | 2013-10-25 | 2016-03-03 | Lpath, Inc. | Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease |
| KR102468519B1 (ko) * | 2015-07-20 | 2022-11-21 | 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 | 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용 |
| BR112019024563A2 (pt) | 2017-05-24 | 2020-06-23 | Transfert Plus S.E.C. | Compostos peptídicos, compostos conjugados e usos dos mesmos para tratar doenças inflamatórias |
| JP7198785B2 (ja) * | 2017-07-05 | 2023-01-04 | ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド | ペプチドの抗炎症的使用 |
| MX2020000029A (es) * | 2017-07-05 | 2020-08-06 | Jiangyin Mucocare Pharmaceutical Co Ltd | Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. |
-
2019
- 2019-09-14 CN CN201980004399.1A patent/CN111601618A/zh active Pending
- 2019-09-14 ES ES19856467T patent/ES2956509T3/es active Active
- 2019-09-14 SG SG11202102119RA patent/SG11202102119RA/en unknown
- 2019-09-14 CA CA3112420A patent/CA3112420A1/en active Pending
- 2019-09-14 FI FIEP19856467.6T patent/FI3678705T3/fi active
- 2019-09-14 SI SI201930561T patent/SI3678705T1/sl unknown
- 2019-09-14 EP EP23176152.9A patent/EP4253404A3/en active Pending
- 2019-09-14 SM SM20230210T patent/SMT202300210T1/it unknown
- 2019-09-14 HU HUE19856467A patent/HUE062848T2/hu unknown
- 2019-09-14 PT PT198564676T patent/PT3678705T/pt unknown
- 2019-09-14 BR BR112021004823-5A patent/BR112021004823A2/pt unknown
- 2019-09-14 KR KR1020217010829A patent/KR102946621B1/ko active Active
- 2019-09-14 CN CN202310240501.6A patent/CN116785447B/zh active Active
- 2019-09-14 MY MYPI2021001220A patent/MY205435A/en unknown
- 2019-09-14 LT LTEPPCT/CN2019/105832T patent/LT3678705T/lt unknown
- 2019-09-14 RS RS20230654A patent/RS64436B1/sr unknown
- 2019-09-14 AU AU2019338582A patent/AU2019338582B2/en active Active
- 2019-09-14 WO PCT/CN2019/105832 patent/WO2020052677A1/en not_active Ceased
- 2019-09-14 DK DK19856467.6T patent/DK3678705T5/da active
- 2019-09-14 JP JP2021514112A patent/JP7759693B2/ja active Active
- 2019-09-14 MX MX2021002657A patent/MX2021002657A/es unknown
- 2019-09-14 HR HRP20230946TT patent/HRP20230946T1/hr unknown
- 2019-09-14 PL PL19856467.6T patent/PL3678705T3/pl unknown
- 2019-09-14 EP EP19856467.6A patent/EP3678705B1/en active Active
- 2019-09-14 US US16/645,355 patent/US11680082B2/en active Active
- 2019-09-16 TW TW108133243A patent/TWI875712B/zh active
-
2021
- 2021-03-01 ZA ZA2021/01398A patent/ZA202101398B/en unknown
- 2021-03-11 SA SA521421448A patent/SA521421448B1/ar unknown
- 2021-03-11 IL IL281426A patent/IL281426A/en unknown
-
2023
- 2023-05-12 US US18/316,496 patent/US20230348536A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005524677A (ja) | 2002-02-22 | 2005-08-18 | ニュー リバー ファーマシューティカルズ インコーポレイテッド | 活性物質送達系及び活性物質を保護し投与する方法 |
| JP2013504579A (ja) | 2009-09-09 | 2013-02-07 | ファーマイン コーポレーション | 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法 |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Non-Patent Citations (1)
| Title |
|---|
| Don A. Cowan,The marine biosphere: a global resource for biotechnology,Trends in Biotechnology,vol.15, no.4,1997年,pp.129-131 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7759693B2 (ja) | モンテルカストおよびペプチドの新規接合体 | |
| JP2026000993A (ja) | 新ペプチド | |
| US20240218016A1 (en) | Peptides and their use in the treatment of inflammation | |
| US20220105082A1 (en) | New formulations containing leukotriene receptor antagonists | |
| RU2838061C9 (ru) | Новые конъюгаты монтелукаста и пептидов | |
| RU2838061C2 (ru) | Новые конъюгаты монтелукаста и пептидов | |
| HK40101414A (en) | Conjugates of montelukast and peptides | |
| US12612430B2 (en) | Peptides | |
| MD3678705T2 (ro) | Conjugați de montelukast și peptide | |
| HK40033390B (en) | Conjugates of montelukast and peptides | |
| HK40033390A (en) | Conjugates of montelukast and peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210315 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220912 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220912 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240925 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241015 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250411 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250527 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250827 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250909 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251009 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7759693 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |